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Introduction 
Scleroderma renal crisis (SRC) is 
characterized by an abrupt onset of 
severe hypertension that is typically 
associated with increased plasma  
renin activity and acute renal failure. 
•  Risk factors include a previous diagnosis of diffuse 
scleroderma, positivity in RNA polymerase III IgG 
autoantibodies and recent use of high dose glucocorticoids. 
•  This case presents a patient who was diagnosed with 
scleroderma renal crisis after a two week course of steroids.
Case Presentation
•  A 57-year-old female with a past medical history of non-
small cell lung cancer (NSCLC) with metastasis to the brain 
and diffuse scleroderma presented to the emergency 
department with a three day history of fatigue and weakness. 
•  She had been receiving radiation therapy for her brain 
metastases and was concurrently taking dexamethasone  
4 mg daily. 
•  One month prior to admission, the patient was seen by 
rheumatology for scleroderma follow up at which point 
positivity of RNA polymerase III autoantibodies was seen on 
lab work. 
•  On admission she had profoundly elevated blood pressures 
without a longstanding history of hypertension. Lab work 
revealed a hemolytic anemia and acute renal failure 
complicated by hyperkalemia and a creatinine 7x her 
baseline. Urinalysis showed proteinuria and hematuria. 
•  Suspicion for SRC was high, but due to hyperkalemia, ACE-
Inhibitors were held at admission. Emergent hemodialysis 
was initiated and captopril was subsequently administered. 
•  Unfortunately, the patient’s hospital course was complicated 
by septic shock and respiratory failure secondary to 
pneumonia. Given her underlying NSCLC and poor prognosis 
her family ultimately decided to proceed with comfort 
measures only. 
Discussion
•  This patient had multiple risk factors for scleroderma renal 
crisis, including a diagnosis of diffuse sclerosis, the presence 
of autoantibodies directed against RNA polymerase III, and 
recent steroid use. 
•  Given her risk factors, closer monitoring of her renal function 
after starting the steroid regimen may have led to an earlier 
diagnosis. 
•  Literature suggests that prompt diagnosis and treatment is 
critical as this can slow irreversible renal injury. For high risk 
patients, literature states that daily home blood pressure 
measurements are recommended. 
•  Early recognition in this case was especially important  
given her co-morbidities. By the time she was admitted,  
her development of hyperkalemia and sepsis made 
administration of ACE-Inhibitors more challenging. 
•  ACE Inhibitors are the initial treatment of choice for SRC, 
with a goal of returning the patient back to his or her 
baseline blood pressure within 72 hours. 
•  If there is central nervous system involvement, intravenous 
nitroprusside can be added for a short duration of therapy. 
•  Had this patient been diagnosed earlier, literature suggests 
that ACE-Inhibitor therapy affects the survival rate at one 
year significantly, from 15% to 76%.
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